

Clinical trials of LMWH

TrialResults-center www.trialresultscenter.org

1 acute coronary syndrome

Trial	Treatments	Patients	Trials design and methods
LMWH vs placebo (on top of aspirin)			
Gurfinkel (LMWH+asp vs asp) , 1995 n=68/73 follow-up: 5-7 days	aspirin plus low molecular weight heparin (214 UIC/kg anti-Xa twice daily subcutaneously versus aspirin (200 mg/day	patients with unstable angina	Parallel groups single blind
LMWH vs UFH (on top of aspirin)			
Gurfinkel (LMWH+asp vs UFH+asp) , 1995 n=68/70 follow-up: 5-7 days	aspirin plus low molecular weight heparin (214 UIC/kg anti-Xa twice daily subcutaneously versus aspirin plus regular heparin (400 IU/kg body weight per day intravenously and titered by activated partial thromboplastin time	patients with unstable angina	Parallel groups single blind

More details and results :

- antithrombotics for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q24>
- heparin (UFH or LMWH) for acute coronary syndrome in all type of patients at <http://www.trialresultscenter.org/go-Q171>

References

Gurfinkel (LMWH+asp vs asp), 1995:

Gurfinkel EP, Manos EJ, Mejia RI, Cerd MA, Duronto EA, Garca CN, Daroca AM, Mautner B Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995 Aug;26:313-8 [7608429]

Gurfinkel (LMWH+asp vs UFH+asp), 1995:

Gurfinkel EP, Manos EJ, Mejia RI, Cerd MA, Duronto EA, Garca CN, Daroca AM, Mautner B Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995 Aug;26:313-8 [7608429]

2 thrombosis prevention

Trial	Treatments	Patients	Trials design and methods
IPC + GCS +LMWH vs GCS +LMWH			
Dickinson , 1998 n=23/21 follow-up: 1 month	sequential compression device +enoxaparin (+ GCS) versus enoxaparin (+GCS)	neurosurgery, patients with brain tumors	open
GCS + LMWH vs LMWH			
Kalodiki (GCS+LMWH vs LMWH) , 1996 n=NA follow-up:	enoxaparin (40 mg once daily) plus graduated elastic compression (TEDR stockings) for 8-12 days versus low molecular weight heparin: (enoxaparin 40 mg once daily)	patients having elective total hip replacement	Parallel groups
LMWH vs UFH			
Harenberg , 1990 n=NA follow-up: 10 days	1 x 1.500 aPTT units of a LMW heparin fraction versus 3 x 5.000 IU of an unfractionated heparin	patients aged 40-80 years	Parallel groups double-blind
Harenberg , 1996 n=NA follow-up: 10 days	1 daily subcutaneous administration of LMW heparin for 10 days versus 3 x 5,000 IU unfractionated (UF) heparin for 10 days	medical inpatients	Parallel groups double-blind

More details and results :

- antithrombotics for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q87>
- graduated compression stockings for thrombosis prevention in all type of patients at <http://www.trialresultscenter.org/go-Q158>
- mechanical devices for thromboprophylaxis for thrombosis prevention in all type of patients at <http://www.trialresultscenter.org/go-Q402>
- mechanical devices for thromboprophylaxis for thrombosis prevention in orthopaedic surgery at <http://www.trialresultscenter.org/go-Q465>
- LMWH for thrombosis prevention in medical patients at <http://www.trialresultscenter.org/go-Q719>

References

Dickinson, 1998:

Dickinson LD, Miller LD, Patel CP, Gupta SK Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. *Neurosurgery* 1998 Nov;43:1074-81 [9802851]

Kalodiki (GCS+LMWH vs LMWH), 1996:

Kalodiki EP, Hoppensteadt DA, Nicolaidis AN, Fareed J, Gill K, Regan F, al-Kutoubi A, Cunningham DA, Birch R, Harris N, Hunt D, Johnson J, Marx C Deep venous thrombosis prophylaxis with low molecular weight heparin and elastic compression in patients having total hip replacement. A randomised controlled trial. *Int Angiol* 1996;15:162-8 [8803642]

Harenberg, 1990:

Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kbler W, Heene DL Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. *Thromb Res* 1990;59:639-50 [2173168]

Harenberg, 1996:

Harenberg J, Roebruck P, Heene DL Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. *Haemostasis* 1996;26:127-39 [8738587]

3 venous thrombosis

33

Trial	Treatments	Patients	Trials design and methods
apixaban (without LMWH) vs LMWH/VKA			
AMPLIFY , 2013 [NCT00643201] n=2691/2704 follow-up: 6 mo	apixaban 10 mg twice daily for 7 days then 5 mg, twice daily, 6 months versus conventional therapy: enoxaparin 1mg/kg twice daily until INR>=2 then warfarin for an INR between 2-4, once daikly, 6 months	patients with deep vein thrombosis or pulmonary embolism	Parallel groups double blind
Botticelli DVT , 2008 [NCT00252005] n=358/118 follow-up:	apixaban 5 mg twice-daily, 10 mg twice-daily, or 20 mg once-daily for 84-91 days versus low molecular weight heparin followed by vitamin K antagonists	patients with symptomatic deep vein thrombosis	Parallel groups open
rivaroxaban (without LMWH) vs LMWH/VKA			
Einstein-DVT Dose-Ranging Study , 2008 n=NA follow-up:	rivaroxaban 20, 30, or 40 mg once daily versus low-molecular-weight heparin followed by vitamin K antagonists	patients with deep vein thrombosis	open

continued...

Trial	Treatments	Patients	Trials design and methods
Einstein-DVT Evaluation , 2010 [NCT00440193] n=1731/1718 follow-up:	rivaroxaban 15 mg twice daily for 3 weeks, then 20 mg daily versus enoxaparin 1 mg/kg twice daily ≥ 5 days, then warfarin with target INR between 2-3	Patients with Confirmed Acute Symptomatic Deep-Vein Thrombosis without Pulmonary Embolism	Parallel groups open (assessor-blind)
Einstein-PE Evaluation , 2012 [NCT00439777] n=2419/2413 follow-up: 9.8 months	rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) for 3, 6, or 12 months versus standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist	patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis	Parallel groups open 38 countries
ximelagatran (without LMWH) vs LMWH/VKA			
THRIVE I , 2003 n=NA follow-up:	oral ximelagatran (24, 36, 48 or 60 mg twice daily) for 2 weeks versus dalteparin and warfarin for 2 weeks	Patients with acute DVT	
LMWH at home vs UFH in hospital			
Koopman , 1996 n=202/198 follow-up: 12 weeks	home treatment with twice daily injections of nadroparin at a dose adjusted for patients weight; versus UH (APTT adjusted dose, continuous intravenous infusion of 1250 IU per hour after initial intravenous bolus of 5000 IU) in hospital.	patients with acute symptomatic proximal DVT proven by venography or duplex scan	Parallel groups open The Netherlands, France, Italy, New Zealand Australia
Boccalon , 2000 n=99/101 follow-up: 6 months	home treatment with sub-cutaneous injection of LMWH (dalteparin sodium, enoxaparin sodium or nadroparin calcium) chosen by the attending physician) at the recommended dose followed by anticoagulant for 6months versus Sub-cutaneous injection of LMWH(dalteparin sodium, enoxaparin sodium or nadroparin calcium as chosen by attending physician) at the recommended dose followed by anticoagulant for 6 months initially in hospital for 10 +/- 2 days then at home	patientst with confirmed diagnosis (by ultrasonography or venography) of proximal DVT not more than 30 days before enrolment	Parallel groups NA France

continued...

Trial	Treatments	Patients	Trials design and methods
Levine , 1996 n=247/253 follow-up: 90 days	home treatment by Sub-cutaneous enoxaparin 1 mg per kg body weight twice a day for at least 5 days versus UH (APTT adjusted dose, continuous intravenous infusion of 20,000 IU after initial intravenous bolus of 5000 IU) in hospital for at least 5 days	patients with acute proximal DVT proven on venography or duplex scan	Parallel groups open Canada
Ramacciotti , 2004 n=104/97 follow-up:	home treatment by once daily Subcutaneous injection of enoxaparin at a dose of 1.5 mg/kg for 5-10 days versus in hospital intravenous bolus injection of 5000 IU of UFH followed by intravenous 500 IU/kg/day adjusted to maintain an aPTT of 1.5-2.5 times the normal value for 5-10 days.	patientst with DVT symptoms for greater than or equal to 10 days and proximal lower limb DVT confirmed by duplex ultrasound or venography	Parallel groups open Brazil
Daskalopoulos , 2005 n=55/53 follow-up:	home treatment with single sub-cutaneous injection of LMWH (tinzaparin sodium) in a weight adjusted dose (175 anti Xa IU/Kg) daily for 6 months versus Intravenous bolus of 5000IU UFH followed by intravenous infusion of UFH for 5-7 days. APTT was measured after 4 hours of the initiation of heparin administration and was repeated 6 hours thereafter to reach the therapeutic range (ratio: 1.5-2.5). Oral an	patients with acute proximal DVT confirmed by colour duplex UScan not more than 1 week onset	Parallel groups open Greece
Chong , 2005 n=150/148 follow-up: 24 months	once daily sub-cutaneous injection of enoxaparin 1.5mg/kg for a minimum of 5 days plus 10mg of warfarin for 3 months adjusted to achieve INR above 2 and within range accepted by the investigator versus 5000 IU bolus of unfractionated heparin (UFH) for a minimum of 5 days plus 10mg warfarin started on day 1 of the treatment for 3 months	patients with diagnosis of symptomatic lower extrimity DVT (proimal or distal) confirmed by either contrast venography and/or ultrasonography, be suitable for treatment in an outpatient setting	Parallel groups open Australia, New Zealand, Poland, South Africa

More details and results :

- antithrombotics for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q101>

- LMWH for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q203>
- heparin (UFH or LMWH) for venous thrombosis in all type of patients at <http://www.trialresultscenter.org/go-Q204>
- direct oral anticoagulant (DAO) for venous thrombosis in all types of patients at <http://www.trialresultscenter.org/go-Q505>

References

AMPLIFY, 2013:

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med* 2013 Aug 29;369:799-808 [23808982] [10.1056/NEJMoa1302507](https://doi.org/10.1056/NEJMoa1302507)

Botticelli DVT, 2008:

Buller H, Deitchman D, Prins M, Segers A Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. *J Thromb Haemost* 2008 Aug;6:1313-8 [18541000]

Einstein-DVT Dose-Ranging Study, 2008:

Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. *Blood* 2008;112:2242-7 [18621928]

Einstein-DVT Evaluation, 2010:

Oral Rivaroxaban for Symptomatic Venous Thromboembolism. *N Engl J Med* 2010 Dec 3;: [21128814] [10.1056/NEJMoa1007903](https://doi.org/10.1056/NEJMoa1007903)

Einstein-PE Evaluation, 2012:

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. *N Engl J Med* 2012 Mar 26;: [22449293] [10.1056/NEJMoa1113572](https://doi.org/10.1056/NEJMoa1113572)

THRIVE I, 2003:

Eriksson H, Whlander K, Gustafsson D, Welin LT, Frison L, Schulman S A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. *J Thromb Haemost* 2003 Jan;1:41-7 [12871538]

Koopman, 1996:

Koopman MM, Prandoni P, Piovela F, Ockelford PA, Brandjes DP, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. *N Engl J Med* 1996;334:682-7 [8594426]

van den Belt AG, Bossuyt PM, Prins MH, Gallus AS, Buller HR Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis—an economic evaluation. *TASMAN Study Group. Thromb Haemost* 1998;79:259-63 [9493572]

Boccalon, 2000:

Boccalon H, Elias A, Chal JJ, Cadne A, Gabriel S Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. *Arch Intern Med* 2000;160:1769-73 [10871969]

Levine, 1996:

Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. *N Engl J Med* 1996;334:677-81 [8594425]

O'Brien B, Levine M, Willan A, Goeree R, Haley S, Blackhouse G, Gent M Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999;159:2298-304 [10547169]

Ramacciotti, 2004:

Ramacciotti E, Arajo GR, Lastoria S, Maffei FH, Karaoglan de Moura L, Michaelis W, Sandri JL, Dietrich-Neto F An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. Thromb Res 2004;114:149-53 [15342210]

Daskalopoulos, 2005:

Daskalopoulos ME, Daskalopoulou SS, Tzortzis E, Sfiridis P, Nikolaou A, Dimitroulis D, Kakissis I, Liapis CD Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 2005;29:638-50 [15878544]

Chong, 2005:

Chong BH, Brighton TA, Baker RI, Thurlow P, Lee CH Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. J Thromb Thrombolysis 2005;19:173-81 [16082604]

4 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
LMWH vs placebo			
Mannarino , 1991 n=22/22 follow-up: 6 mois	Hparine de bas poids molculaire(PM= 5000 Dalton), 15000 U od sc versus Placebo en seringues prremplies de mme aspect que le traitement	AOMI stade II	Parallel groups Double aveugle
Calabro , 1993 n=18/18 follow-up: 6 mois	Hparine de bas poids molculaire versus Placebo	AOMI stade II	Parallel groups Double aveugle

More details and results :

- antithrombotics for peripheral vascular diseases in all type of patients at <http://www.trialresultscenter.org/go-Q50>

References

Mannarino, 1991:

Mannarino E, Pasqualini L, Innocente S, Orlandi U Efficacy of low molecular weight heparin in the management of intermittent claudication Angiology 1991;42:1-7

Calabro, 1993:

Alessio Calabro, Francesco Piarulli, Daniele Milan,Alberto Rossi, Giovanna Coscetti Clinical assessment of low molecular weight heparin . Effects in peripheral vascular disease angiology 1993;44:188-195

5 pulmonary embolism

Trial	Treatments	Patients	Trials design and methods
apixaban (without LMWH) vs LMWH/VKA			
AMPLIFY , 2013 [NCT00643201] n=2691/2704 follow-up: 6 mo	apixaban 10 mg twice daily for 7 days then 5 mg, twice daily, 6 months versus conventional therapy: enoxaparin 1mg/kg twice daily until INR.>=2 then warfarin for an INR between 2-4, once daikly, 6 months	patients with deep vein thrombosis or pulmonary embolism	Parallel groups double blind
rivaroxaban (without LMWH) vs LMWH/VKA			
Einstein-PE Evaluation , 2012 [NCT00439777] n=2419/2413 follow-up: 9.8 months	rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) for 3, 6, or 12 months versus standard therapy with enoxaparin followed by an adjusted-dose vitamin K antagonist	patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis	Parallel groups open 38 countries

∞

More details and results :

- antithrombotics for pulmonary embolism in all type of patients at <http://www.trialresultscenter.org/go-Q102>

References

AMPLIFY, 2013:

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013 Aug 29;369:799-808 [23808982] [10.1056/NEJMoa1302507](https://doi.org/10.1056/NEJMoa1302507)

Einstein-PE Evaluation, 2012:

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med 2012 Mar 26;: [22449293] [10.1056/NEJMoa1113572](https://doi.org/10.1056/NEJMoa1113572)

6 superficial thrombophlebitis

Trial	Treatments	Patients	Trials design and methods
LMWH vs heparin spraygel			

continued...

Trial	Treatments	Patients	Trials design and methods
Gorski (LMWH vs hep spraygel) , 2005 n=NA	-	-	
Katzenschlager (LMWH vs hep spraygel) , 2003 n=NA	-	-	
LMWH vs low dose heparin			
Belcaro (LMWH vs low dose hep) , 1999 n=NA follow-up:	LMWH versus low-dose subcutaneous heparin	Patients with ST and large varicose veins	
Fixed-dose LMWH vs NSAIDs			
STENOX (enox fixed dose vs NSAIDs) , 2003 n=NA	-	-	
Prophylactic LMWH vs NSAIDs			
STENOX (prophylactic LMWH vs NSAIDs) , 2003 n=NA	-	-	
Therapeutic LMWH vs saphenofemoral disconnection			
Lozano , 2003 n=NA follow-up:	Enoxaparin 1mg/kg twice daily for the first week, then 1mg/kg for 3 weeks versus saphenofemoral disconnection	patients with saphenous proximal thrombophlebitis	

More details and results :

- antithrombotics for superficial thrombophlebitis in superficial thrombophlebitis of the leg at <http://www.trialresultscenter.org/go-Q218>

References

Gorski (LMWH vs hep spraygel), 2005:

Katzenschlager (LMWH vs hep spraygel), 2003:

Belcaro (LMWH vs low dose hep), 1999:

Belcaro G, Nicolaides AN, Errichi BM, Cesarone MR, De Sanctis MT, Incandela L, Venniker R Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study. *Angiology* 1999;50:523-9 [[10431991](#)]

STENOX (enox fixed dose vs NSAIDs), 2003:

A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med 2003 Jul 28;163:1657-63 [[12885680](#)]

STENOX (prophylactic LMWH vs NSAIDs), 2003:

A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med 2003 Jul 28;163:1657-63 [[12885680](#)]

Lozano, 2003:

Lozano FS, Almazan A Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: a prospective study. Vasc Endovascular Surg 2003;37:415-20 [[14671696](#)]

Entry terms: apixaban, BMS 562247, BMS562247, BMS-562247, Eliquis, , rivaroxaban, Xarelto, BAY 59-7939, , ximelagatran, ximelagatran, xi-melagatran, Exanta, H 376 95, H 376-95,